LIVZON PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement.

We accept no liability for any loss caused by reliance on such content.

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "Livzon Pharmaceutical Group Co., Ltd." published on the website of the Shenzhen Stock Exchange Co., Ltd.’s Announcement on the General Election of the Board of Directors” is for reference only.

By order of the board of directors

Livzon Pharmaceutical Group Co., Ltd. LivzonPharmaceuticalGroupInc.* company secretary Liu Ning

China, Zhuhai April 23, 2026

As of the date of this announcement, the executive director of the company is Mr. Tang Yanggang (vice chairman); the non-executive director of the company is Mr. Zhu Baoguo. Sheng (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the company’s employee director is Ms. Ran Yongmei; and the company’s independence is not

The executive directors are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

*Identification only

Securities code: 000513, 01513 Securities abbreviation: Livzon Group, Livzon Pharmaceutical Announcement number: 2026-25

Livzon Pharmaceutical Group Co., Ltd.

Announcement on the General Election of the Board of Directors

The company and all members of the supervisory board guarantee that the information disclosed is true, accurate, complete and not false.

records, misleading statements or material omissions.

The term of the 11th Board of Directors of Livzon Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") is about to begin. Upon expiration, in accordance with the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law") and the Shenzhen Securities Exchange

Exchange Stock Listing Rules" "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Main Board

Municipal Company Standardized Operations" (hereinafter referred to as "Standardized Operations") and the "Chapter of Livzon Pharmaceutical Group Co., Ltd."

According to the relevant provisions of the Articles of Association (hereinafter referred to as the "Articles of Association"), the company conducted a general election of the board of directors. Present general

The relevant announcement is as follows:

1. General election of the board of directors

The company held the 34th meeting of the 11th board of directors on April 23, 2026, and reviewed and approved

"Proposal on Nominating Non-Independent Director Candidates for the Company's Twelfth Board of Directors" "On Nominating the Company's Tenth Board of Directors"

Proposal on Candidates for Independent Directors of the Second Board of Directors". The company's twelfth board of directors will consist of 10 directors.

Among them, there are 6 non-independent directors (including 1 employee representative director) and 4 independent directors. Company Board Nomination

Mr. Zhu Baoguo, Mr. Lin Nanqi and Mr. Qiu Qingfeng are candidates for non-executive directors of the 12th Board of Directors of the company. Nominate Mr. Liu Daping and Mr. Tang Yanggang as executive director candidates for the 12th Board of Directors of the company, and nominate Luo Hui

Mr. Yuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li are independent and non-executive members of the 12th board of directors of the company.

The term of director candidates shall be three years from the date of review and approval by the shareholders' meeting. Please see the attachment for resume details. The company will call another

Convene an employee representative meeting to elect employee representative directors.

2. Qualifications of director candidates

The Company’s Nomination Committee reviewed the qualifications of the above-mentioned director candidates and concluded that the above-mentioned director candidates The selection of candidates complies with the "Company Law", "Shenzhen Stock Exchange Stock Listing Rules", "Standardized Operations" and "Company Articles"

According to the director's qualifications stipulated in the "Procedures" and other provisions, there are no circumstances that prohibit him from serving as a director of the company.

As of the disclosure date of this announcement, Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li have all

Obtained independent director qualification certificate, among which Ms. Kang Li is an accounting professional. independent director candidates

Only after the qualifications and independence have been reviewed by the Shenzhen Stock Exchange and there are no objections, can they be submitted to the company's shareholders' meeting for review.

The number of independent director candidates mentioned above shall not be less than one-third of the number of directors on the board of directors, and the number of candidates on the board of directors shall be

The total number of senior managers and directors held by employee representatives does not exceed two-half of the total number of directors of the company.

one.

3. Other instructions

In order to ensure the normal operation of the board of directors, before the directors of the new board of directors take office, the eleventh director of the company The directors will comply with the requirements of laws, administrative regulations and other normative documents and the provisions of the Articles of Association.

Earnestly perform the duties of directors.

4. Documents available for inspection

(1) Resolution of the 34th meeting of the 11th Board of Directors of the company;

(2) Resolution of the 13th meeting of the Nomination Committee of the 11th Board of Directors of the Company.

Attachment: Resumes of Director Candidates for the 12th Board of Directors of the Company

Announcement is hereby made.

Board of Directors of Livzon Pharmaceutical Group Co., Ltd.

April 24, 2026

Attachment: Resumes of Director Candidates for the 12th Board of Directors of the Company (in no particular order)

Mr. Zhu Baoguo, born in 1962, is currently the Chairman, Non-executive Director and Strategic Committee Chairman of the Company. Chairman and Chairman of the Environmental, Social and Governance Committee. Graduated from the Chemistry Department of Henan Normal University in 1985 and received the

Bachelor's degree. He has been the Chairman of the Company since 2002, from April 2006 to September 2013.

During this period, he also served as the president of the company. Mr. Zhu Baoguo is the founder of Joincare Pharmaceutical Group Co., Ltd. and is currently

He serves as the chairman of the company and currently serves as the honorary vice president of the Shenzhen Federation of Industry and Commerce (General Chamber of Commerce) and the Nature Conservation Association.

Director and Executive Secretary of the Greater China Council (TNC), Director of the Shenzhen Chamber of Commerce and Shenzhen Chamber of Commerce, Chairman of Taohuayuan Ecological Protection Foundation. From May 2021 to October 2024, he served as Zhongyuan Construction Co., Ltd.

Independent non-executive director of the company (09982.HK).

As of the disclosure date of this announcement, Mr. Zhu Baoguo does not hold any shares in the company. Mr. Zhu Baoguo is the company’s actual

The controller, who is married to Ms. Liu Guangxia, is the controlling shareholder of the company, Joincare Yuan Pharmaceutical Group Co., Ltd.

serves as the chairman of the board of directors and has no relationship with other directors and senior managers of the company; he has not received any certification from China Securities Regulatory Commission. Penalties imposed by the Supervisory Board and other relevant departments and disciplinary sanctions imposed by stock exchanges have not been imposed by judicial authorities for suspected crimes.

A case has been opened for investigation or suspected of violating laws and regulations and has been opened for investigation by the China Securities Regulatory Commission; has not been investigated by the China Securities Regulatory Commission during the securities period

The illegal and untrustworthy information in the commodity market shall be published on the public inquiry platform or included in the list of persons subject to execution for untrustworthy conduct by the People's Court;

There are no circumstances that prohibit nomination as a director as stipulated in the "Standardized Operations"; there are no circumstances under the "Company Law" and "Shenzhen Securities"

Those who are not allowed to serve as directors are prohibited from serving as directors as stipulated in the Stock Exchange Stock Listing Rules, Articles of Association, etc.; Judiciary, Articles of Association, etc.

Mr. Liu Daping, born in 1987, is currently the President of the Company. Bachelor's degree from China Pharmaceutical University. once

Served as technician, workshop director and production director of Shenzhen Haibin Pharmaceutical Co., Ltd., Shenzhen Taitai Pharmaceutical Co., Ltd.

Executive deputy general manager of the company, deputy director of the production management center of Joincare Pharmaceutical Group Co., Ltd. and Mrs. Shenzhen General Manager of Pharmaceutical Co., Ltd. From January 2024 to February 2026, he will serve as Vice President of the Company.

As of the disclosure date of this announcement, Mr. Liu Daping does not hold any shares of the company. Mr. Liu Daping and the holding company

There is no related relationship between shareholders, actual controllers and other directors and senior managers of more than 5% of the shares;

He has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions from stock exchanges, and has not been suspected of committing any crime.

has been investigated by the judicial authorities or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; has not been investigated by the China Securities Regulatory Commission; The Regulatory Commission has disclosed illegal and untrustworthy information in the securities and futures markets on the public inquiry platform or been listed as untrustworthy by the people's court.

List of persons subject to execution; there are no circumstances that prohibit nomination as directors as stipulated in the "Standardized Operations"; there are no circumstances under the "Standardized Operations";

Those who are prohibited from serving as directors as stipulated in the Judiciary, Shenzhen Stock Exchange Stock Listing Rules, Articles of Association, etc.

Circumstances; comply with the employment requirements stipulated in the Company Law, Articles of Association, etc.

Mr. Tang Yanggang, born in 1969, currently serves as Executive Director, Vice Chairman, Remuneration and Appraisal Director of the Company.

Member of the Committee, Nomination Committee, Strategy Committee and Environmental, Social and Governance Committee.

Graduated from Sichuan University in 1992, majoring in microbiology, with a bachelor's degree. Senior pharmaceutical engineer. 2008

Joined Xinbeijiang Pharmaceutical in 2006 and served successively as technical director, general manager, chairman and party committee secretary of Xinbeijiang Pharmaceutical. From July 2015 to present, he serves as the chairman of Xinbeijiang Pharmaceutical. From July 2015 to October 2020, Ren Ben

General Manager of the Company’s API Business Department; from December 2018 to February 2026, he served as President of the Company. concurrently

Vice President of China Traditional Chinese Medicine Association, Vice Chairman of Guangdong Pharmaceutical Association, Member of Zhuhai Municipal People’s Political Consultative Conference, Qingyuan Entrepreneurs Association

Vice president of the meeting. Since March 2023, he has served as a member of the Standing Committee of the Executive Committee of the Zhuhai Federation of Industry and Commerce and the General Secretary of Zhuhai City.

Executive Director of the Chamber of Commerce Council. As of the disclosure date of this announcement, Mr. Tang Yanggang holds 344,963 A shares of the company. Tang Yanggangxian

There are no shareholders, actual controllers and other directors and senior managers who hold more than 5% of the company’s shares.

In the related relationship; has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions by the stock exchange,

Has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations;

It has not been disclosed by the China Securities Regulatory Commission’s illegal and untrustworthy information disclosure platform in the securities and futures markets or by the people. The court has included the list of dishonest persons subject to execution; there are no circumstances that prohibit nomination as a director as stipulated in the "Standardized Operations";

Without the provisions of the Company Law, the Stock Listing Rules of the Shenzhen Stock Exchange, the Articles of Association, etc.

Circumstances of serving as a director; complying with the requirements of the Company Law, Articles of Association, etc.

Mr. Lin Nanqi, born in 1982, is currently a non-executive director of the Company. Graduated from Tianjin University of Commerce (formerly Tianjin Business College) received a bachelor's degree in engineering. Served as manager of Livzon Group Xinbeijiang Pharmaceutical Co., Ltd.

Interim manager, production director, deputy general manager, general manager and chairman of Jiaozuo Healthyuan Biological Products Co., Ltd.

General manager and director of Shenzhen Haibin Pharmaceutical Co., Ltd., executive director and health director of Shenzhen Taitai Pharmaceutical Co., Ltd.

Executive Vice President of Yuan Pharmaceutical Group Co., Ltd. and other positions. Current job: Joincare Yuan Pharmaceutical Group Co., Ltd.

Director, President. As of the disclosure date of this announcement, Mr. Lin Nanqi does not hold any shares in the company. In addition to working in the controlling shareholder unit

In addition, Mr. Lin Nanqi and other shareholders, actual controllers and other directors who hold more than 5% of the company’s shares,

There is no related relationship among the senior managers; they have not been punished by the China Securities Regulatory Commission and other relevant departments.

The exchange has not been subject to disciplinary sanctions and has not been investigated by judicial authorities for suspected crimes or prosecuted by China for suspected violations of laws and regulations. The China Securities Regulatory Commission has opened a case for investigation; it has not been investigated by the China Securities Regulatory Commission for illegal and untrustworthy information in the securities and futures markets.

Publicly announced or included in the list of dishonest persons subject to enforcement by the people's court; those who do not meet the provisions of "Standardized Operations" shall not be mentioned

The situation of being named a director; there is no "Company Law", "Shenzhen Stock Exchange Stock Listing Rules", "Company Articles"

Those who are not allowed to serve as directors are prohibited from serving as directors as stipulated in the Articles of Association and other provisions;

request.

Mr. Qiu Qingfeng, born in 1971, is currently a non-executive director of the Company. China Europe International Business School High School

Executive MBA degree. Non-practising member of the Chinese Certified Public Accountants. Since 1996, he has served as

Financial staff, financial director, financial department manager, deputy general manager of Kangyuan Pharmaceutical Group Co., Ltd.

General manager and other positions, currently serving as director, vice president and financial director of Joincare Pharmaceutical Group Co., Ltd. From June 2005 to April 2007, he served as supervisor and chief supervisor of the Company.

As of the disclosure date of this announcement, Mr. Qiu Qingfeng does not hold any shares in the company. In addition to working in the controlling shareholder unit

In addition, Mr. Qiu Qingfeng and other shareholders, actual controllers and other directors who hold more than 5% of the company’s shares,

There is no related relationship among the senior managers; they have not been punished by the China Securities Regulatory Commission and other relevant departments.

The exchange has not been subject to disciplinary sanctions and has not been investigated by judicial authorities for suspected crimes or prosecuted by China for suspected violations of laws and regulations. The China Securities Regulatory Commission has opened a case for investigation; it has not been investigated by the China Securities Regulatory Commission for illegal and untrustworthy information in the securities and futures markets.

Publicly announced or included in the list of dishonest persons subject to enforcement by the people's court; those who do not meet the provisions of "Standardized Operations" shall not be mentioned

The situation of being named a director; there is no "Company Law", "Shenzhen Stock Exchange Stock Listing Rules", "Company Articles"

Those who are not allowed to serve as directors are prohibited from serving as directors as stipulated in the Articles of Association and other provisions;

request.

Mr. Luo Huiyuan, born in 1966, currently serves as an independent non-executive director and a member of the Audit Committee of the Company.

and Chairman of the Nomination Committee. Master of Laws from Renmin University of China. Currently on the management committee of Beijing Hairun Tianrui Law Firm

Director and senior partner. He concurrently serves as the vice president of Beijing Chaoyang District Lawyers Association. Former owner of Tibet Tianlu Co., Ltd.

Co., Ltd. (600326.SH) Independent Director, Shanghai Jialinjie Textile Co., Ltd. (002486.SZ) Independent Director, Independent Director of China Petroleum Corporation Capital Co., Ltd. (000617.SZ), Xianheng International

Independent Director of Science and Technology Co., Ltd. (605056.SH), Independent Director of China Xiaxin Intelligent IoT Co., Ltd.

Independent director; currently independent director of Zhuque Fund Management Co., Ltd. and Nanjing Reindeer Biotechnology Co., Ltd.

Independent Director. As of the disclosure date of this announcement, Mr. Luo Huiyuan does not hold any shares in the company. Mr. Luo Huiyuan and the holding company

There is no related relationship between shareholders, actual controllers and other directors and senior managers of more than 5% of the shares;

He has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions from stock exchanges, and has not been suspected of committing any crime.

has been investigated by the judicial authorities or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; has not been investigated by the China Securities Regulatory Commission;

The Regulatory Commission has disclosed illegal and untrustworthy information in the securities and futures markets on the public inquiry platform or been listed as untrustworthy by the people's court. List of persons subject to execution; there are no circumstances that prohibit nomination as directors as stipulated in the "Standardized Operations"; there are no circumstances under the "Standardized Operations";

Those who are prohibited from serving as directors as stipulated in the Judiciary, Shenzhen Stock Exchange Stock Listing Rules, Articles of Association, etc.

Circumstances; comply with the employment requirements stipulated in the Company Law, Articles of Association, etc.

Ms. Cui Lijie, born in 1975, currently serves as an independent non-executive director and remuneration and assessment committee member of the Company. Chairman of the Board, members of the Audit Committee, members of the Nomination Committee and members of the Environmental, Social and Governance Committee. once

Served as director of Zhuhai Yibang Pharmaceutical Co., Ltd., secretary of the board of directors of Zhuhai Yibang Pharmaceutical Co., Ltd., Su

Supervisor, non-independent director of Zhou Ailong Technology Co., Ltd. (688329.SH), Zhuhai Taichuan Cloud Community Technology

Independent Director of Technology Co., Ltd. (832214.NEEQ). Currently a member of the CPPCC Committee of Jinwan District, Zhuhai City

And executive committee member of Zhuhai Jinwan District Women’s Federation, vice president of Zhuhai Intellectual Women’s Federation, Zhuhai Longmen Capital Chairman of Management Co., Ltd., Executive Director and General Manager of Zhuhai Longmen Medical Investment Co., Ltd., Zhuhai Hengqin

Executive Director and General Manager of Longmen Investment Co., Ltd., Director of Suzhou Yusen New Drug Co., Ltd., Deyi Sunshine (Beijing)

Director of Beijing) Co., Ltd. and Director of Shenzhen Qianhai Longqishi Information Technology Co., Ltd.

As of the disclosure date of this announcement, Ms. Cui Lijie does not hold any shares in the company. Ms. Cui Lijie and the holding company

There is no related relationship between shareholders, actual controllers and other directors and senior managers of more than 5% of the shares; He has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions from stock exchanges, and has not been suspected of committing any crime.

has been investigated by the judicial authorities or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; has not been investigated by the China Securities Regulatory Commission;

The Regulatory Commission has disclosed illegal and untrustworthy information in the securities and futures markets on the public inquiry platform or been listed as untrustworthy by the people's court.

List of persons subject to execution; there are no circumstances that prohibit nomination as directors as stipulated in the "Standardized Operations"; there are no circumstances under the "Standardized Operations";

Those who are prohibited from serving as directors as stipulated in the Judiciary, Shenzhen Stock Exchange Stock Listing Rules, Articles of Association, etc. Circumstances; comply with the employment requirements stipulated in the Company Law, Articles of Association, etc.

Ms. Wang Zhiyao, born in 1986, is currently the independent non-executive director and environmental, social and management director of the Company.

Member of the Governance Committee. Graduated from Xi'an Jiaotong University with a bachelor's degree in clinical medicine and Renmin University of China with a bachelor's degree in clinical medicine.

Master of Public Administration, Harvard University and Master of Finance. Worked at the Chinese Academy of Medical Sciences Tissue Engineering Research Center, Sanofi China R&D Center, Novartis Global R&D Headquarters. Formerly a medical officer in Suzhou

Founder and CEO of BioShin Limited and founding general manager of BioShin Limited

and Chief Operating Officer, Hong Kong Avenex Biosciences Limited (Avenex Biosciences Limited) Management Partner

Partner; currently studying for a PhD in Biomedicine at the University of Hong Kong.

As of the disclosure date of this announcement, Ms. Wang Zhiyao does not hold any shares in the company. Ms. Wang Zhiyao and the holding company There is no related relationship between shareholders, actual controllers and other directors and senior managers of more than 5% of the shares;

He has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplinary sanctions from stock exchanges, and has not been suspected of committing any crime.

has been investigated by the judicial authorities or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; has not been investigated by the China Securities Regulatory Commission;

The Regulatory Commission has disclosed illegal and untrustworthy information in the securities and futures markets on the public inquiry platform or been listed as untrustworthy by the people's court.

List of persons subject to execution; there are no circumstances that prohibit nomination as directors as stipulated in the "Standardized Operations"; there are no circumstances under the "Standardized Operations"; Those who are prohibited from serving as directors as stipulated in the Judiciary, Shenzhen Stock Exchange Stock Listing Rules, Articles of Association, etc.

Circumstances; comply with the employment requirements stipulated in the Company Law, Articles of Association, etc.

Ms. Kang Li, born in 1973, Chinese nationality, no permanent residence abroad, PhD in Economics, Note

Certified Public Accountant. Served as a visiting scholar at the Berlin School of Finance and Economics in Germany and the Berlin University of Applied Sciences, West Georgia, USA University visiting scholar, teaching assistant and lecturer at the School of Finance, Zhongnan University of Economics and Law, Vini Health (Shenzhen) Co., Ltd.

Co., Ltd., independent director of Shenzhen Zhili Precision Technology Co., Ltd. (300686.SZ)

things. Currently, he is an associate professor at the School of Finance, Zhongnan University of Economics and Law, Hunan Haohua Chemical Co., Ltd. (not listed above)

Municipal Company), Shandong Saito Biotechnology Co., Ltd. (300583.SZ), Wuhan Zhongke Tongda High-tech

Independent director of Technology Co., Ltd. (688038.SH). As of the disclosure date of this announcement, Ms. Kang Li does not hold any shares in the company. Ms. Kang Li holds 5% of the company

The shareholders, actual controllers and other directors and senior managers of the above shares have no related relationship; they are not affected by

He has been punished by the China Securities Regulatory Commission and other relevant departments and disciplinary sanctions by stock exchanges, and has never been punished for suspected crimes.

The judicial authority has opened a case for investigation or the China Securities Regulatory Commission has opened a case for investigation for suspected violations of laws and regulations; it has not been investigated by the China Securities Regulatory Commission.

In the securities and futures markets, the illegal and untrustworthy information is disclosed on the public inquiry platform or is listed as being punished for breach of trust by the people's court. List of pedestrians; there is no situation that prohibits nomination as a director stipulated in the "Standardized Operations"; there is no "Company Law"

Circumstances that stipulate in the "Shenzhen Stock Exchange Stock Listing Rules", "Articles of Association", etc. that you are not allowed to serve as a director;

Comply with the employment requirements stipulated in the Company Law, Articles of Association, etc.